Global Cardiac Biomarkers Market Trends, Analysis, Segmentation and Forecast, 2012 - 2020

PORTLAND, Ore. - June 16, 2015 - PRLog -- Cardiac Biomarkers are protein substances released into the blood stream from damaged heart muscles. These are the biological parameters that are used to detect the presence of cardiovascular diseases. According to World Health Organization, in 2008, 17.3 million people died due to cardiovascular diseases and it is expected to reach 23.3 million by 2030. This increase in cardiovascular diseases across the globe widens the global cardiac biomarkers market. With the prevalence of these cardiovascular diseases, demand for cardiac biomarkers would increase in future for early diagnosis and disease management. The study will help to identify the opportunities for global players in the cardiac biomarkers market to generate maximum profit.

The major drivers for growth of cardiac biomarkers are increase in number of cardiovascular diseases, ageing population and precision of cardiac biomarkers in early detection of risks associated with cardiovascular diseases. The restraints for cardiac biomarkers market are side effects related to biomarkers such as skeletal muscle injury and their less specific actions in detecting the presence of cardiovascular diseases.

Get full report & TOC @: http://www.researchbeam.com/cardiac-biomarkers-market

Cardiac biomarkers Type Market analysis
Cardiac biomarker type market is segmented in enzymatic and non enzymatic cardiac biomarkers. Enzymatic cardiac biomarker includes myocardial muscle creatine kinase CK (MB), Lactate dehydrogenase (LDH 1), Aspartate Transaminase (AST), Myleperoxidase, Matrix metalloproteinase and Non enzymatic cardiac biomarker includes Troponins(T,I),Myoglobin, Pro-brain natriuretic peptide, and Ischemia modifies albumin. Tropoin T and I are preferred mostly for the diagnosis of myocardial infarction due to its highest sensitivities and specificities.

Cardiac biomarkers Application Market analysis
Cardiac biomarkers application market analysis is segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction is the leading cause of mortality in developed countries.

Cardiac biomarkers Geographic Market analysis
Geographically, the market is segmented into North America, Europe, Asia Pacific and rest of the world. The global cardiac biomarker market is dominated by North America and Europe due to increasing patient population suffering from cardiovascular diseases, lack of physical activities and unhealthy diet. India, South East Asia and china are the emerging markets for cardiac biomarkers due to increase in incidence of coronary artery diseases.

Competitive landscape
Key players of cardiac biomarker market are Ortho-clinical diagnostics, Abbott laboratories, Roche Diagnostics Corporation, Medtronic, Inc. Biosensors International Ltd. and others. The strategies adopted by these players are Product launch, merger and acquisition and research development collaborations. Product launch strategy is adopted by most of the players. Roche Diagnostics introduces Cobas-H232 Handheld cardiac Marker system II-38, a cardiac biomarker used for the diagnosis of cardiovascular diseases.

High level analysis
Cardiac biomarkers market is analyzed through Porter’s five forces model, which explains that bargaining power of supplier varies with application of cardiac biomarkers and bargaining power of buyers is less as cost of switching is high .Threat of new entrant is less as high capital investment is require for new start-up. SWOT analysis provides a way for making strategic business decisions. The business strategies adopted by the key players are analyzed. The impact of drivers for growth, restraints and opportunities for cardiac biomarkers market is described in detail.

Enquire about report @: http://www.researchbeam.com/cardiac-biomarkers-market/enquire-about-report

Key Benefits
In depth analysis of cardiac biomarker market, which is segmented on the basis of type, application and geography provides clear understanding of the market.
Quantitative analysis of the current market and estimations through 2013-2020. Thus helping cardiac biomarker marketers to analyze the market.
Assessment and ranking of the factors affecting the global market and their impact on the cardiac biomarker market.
Study on the bargaining power of buyers and suppliers in the market, based on porter’s five force analysis. Thus helping cardiac biomarker manufacturer to analyze the market.
SWOT and competitive analysis of the key players, which would help stakeholders to understand trends followed by their competitors and take actionable decisions.


Key Deliverables
The global cardiac biomarker market is segmented based on type, application, and geography.

Market by Type
Enzymatic
Myocardial Muscle Creatine Kinase (CK(MB))
Lactate Dehydrogenase (LDH 1)
Aspartate Transaminase (AST)
Myleperoxidase
Matrix Metalloproteinase
Non Enzymatic
Troponins(T,I)

Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others

Market by Geography
North America
Europe
Asia Pacific
Rest of the world